A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

HIV Infections Clinical Trial

— Rollover  

Official title:

A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00622232
• Other study ID #: VRX496-USA-05-002-Rollover
• Status: Active, not recruiting
• Phase: Phase 2
• First received: February 11, 2008
• Last updated: June 7, 2011
• Start date: December 2007
• Est. completion date: June 2023

Study information

• Verified date: June 2011
• Source: VIRxSYS Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to determine the long term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells with a focus on evaluating additional therapeutic benefits with respect to viral load and CD4 counts.

Description:

The study has concluded it's 9-month active phase. Subjects are currently in a 15-year Long Term Follow-up Phase of the study.

In keeping with the recently released Guidance on Monitoring For Delayed Adverse Events, that states that for the first 5 years all subjects should undergo monitoring of vector sequences every 6 months, subjects will visit the clinic at a maximum of 6 months intervals for a blood test evaluating persistence of vector sequences.

Therefore for the first 5 years, subjects will have 6 months visits for safety assessment. For years 6 to 15, subjects will be contacted by phone or mail. At these contacts, subjects will be asked about their health status.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: June 2023
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability and willingness to give written informed consent in accordance with institutional and federal guidelines and to comply with the investigational nature of the study and the related requirements.

• Subjects who have successfully completed participation in the VRX496-USA-05-002 trial.

• Subjects who initiated or changed to a new ARV regimen more than 3 months prior to Entry Assessment are eligible.

• Subjects that who (1) if on ARVs and are willing to continue on the current therapy unchanged, or (2) if not on ARV willing to remain off ARVs for the duration of the trial i.e. 9 months. However, if there is clinical need to start or change ARV therapy, then it is permitted to do so.

Exclusion Criteria:

• CD4 counts decreased by =25% from baseline in main study.

• Viral load increased by = 1.0 log from baseline in main study or = 200,000.

• Female subjects who are of reproductive potential who have a positive serum B HCG at the Entry Assessment visit or are not willing to use a reliable method of barrier contraception.

• Are breast-feeding.

• Subjects who are actively using injection drugs or other substance abuse (such as extensive alcohol or narcotic use).

• Any medical condition(s) which, in the opinion of the investigator, would interfere with the subject's ability to participate in or adhere to the requirements of this protocol

• Active HIV-related or non HIV-related illness

• Subjects who do not have additional cell product available

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Genetic:
• VRX496-transduced autologous CD4 T cells
The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.

Locations

Country	Name	City	State
United States	Jacobi Medical Center	New York	New York
United States	CIRCLE Medical, LLC	Norwalk	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
VIRxSYS Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability of an additional infusion of VRX496 CD4+ T cells in subjects who previously received VRX496 CD4 T cells under protocol VRX496-USA-05-002.		9 months	Yes
Primary	To evaluate the change in log10 HIV-1 RNA level		9 months	Yes
Primary	To evaluate the change between main study baseline CD4 counts and Month 9 post reinfusion		9 months	No
Secondary	Changes in immune function as determined by ICS and TCR vß Repertoire profile.		9 months	No